Age-related mild cognitive deficit: a ready-to-use concept? by Gilles, Christian
hile promising therapeutic strategies are being
explored, our capacity to diagnose dementias early in
their evolution remains poor. Degenerative dementias
are insidious and progressive in nature. It is therefore
conceivable that a dementia picture is preceded by a
“preclinical state” (ie, pathognomonic cerebral lesions
coexisting with normal cognition) as described in
Alzheimer’s disease (AD),
1,2 followed by mild deficits
first experienced by patients themselves,then suspected
by their family members, and eventually demonstrated
through neuropsychological examination.
It is generally assumed that normal aging involves cogni-
tive changes,displaying large inter- and intraindividual
variability.
3 Some studies challenged this common view,
showing that the use of strict criteria for the inclusion of
cognitively normal subjects in longitudinal studies demon-
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Age-related mild cognitive deficit:
a ready-to-use concept?
Christian Gilles, MD
W
For better management of mild cognitive impairment in elderly patients, clinicians should be provided with instruments
to detect early changes and predict their progression. To define this cognitive status between optimal and pathological
aging, many concepts have been proposed, which actually describe various conditions and provide more or less precise
criteria, leaving room for variable implementation. As a consequence, application of these criteria gave highly variable
prevalence rates. Neuropathological studies indicate that the different criteria have variable power in detecting incipi-
ent Alzheimer’s disease (AD) and suggest that the transition between mild cognitive impairment and AD is not merely
quantitative. Follow-up studies have produced, according to the criteria used, a 2.5% to 16.6% annual rate for pro-
gression toward dementia, and have also shown that the criteria differ in their stability and predictive power. Baseline
cognitive performances have some predictive value, but are difficult to apply in first-line medicine. Investigational tech-
niques (structural and functional imaging, magnetic resonance spectroscopy, magnetization transfer imaging, cerebrospinal
fluid neuro-chemistry, and apolipoprotein E genotype) are promising tools in the early diagnosis of AD, which remains
the most frequent type of dementia in elderly people and probably the most frequent type developed by patients with
mild cognitive deficit. The final goal is to offer early treatment to those patients who will evolve towards dementia, once
they can be identified. In the case of AD, recent findings question the adequacy of cholinergic replacement therapies. In
its current state, the criteria for mild cognitive deficit are hardly transferable to first-line medicine. However, dissemi-
nating the concept could help increase the sensitivity of general practitioners to the importance of cognitive complaints
and signs in their elderly patients.
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4-7 It was therefore argued that
the elderly populations who were the basis of the “normal
cognitive aging”concept were contaminated by individu-
als with very mild dementia.
1,8,9
As a result,there is currently no consensus on the defini-
tion or on the meaning of mild cognitive deficit in an
older individual, or on the attitude it should trigger in
physicians.Periodic reassessment until the criteria for a
dementia syndrome are fulfilled,as is currently practiced,
avoids the risks of overdiagnosis, but conveys those of
delaying the initiation of an effective treatment.This daily
clinical dilemma would be resolved if physicians were
provided with simple instruments allowing a clear differ-
entiation between normal and prodromal cognitive status
in a given elderly patient.The goal of this review is to
assess to what extent this need is currently met.
Main concepts and criteria
Since Kral’s benign senescent forgetfulness,
10 several
concepts have been proposed to understand this shad-
owy zone between optimal and pathological cognitive
aging (Table I).
10-23
Cognitive impairment–no dementia (CIND) identifies
cognitive impairment associated with various conditions,
ranging from age-associated memory impairment
(AAMI)
15 to cerebrovascular or general vascular diseases,
to depression.
22,24 Mild cognitive disorder in the Diagnostic
and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV)
20 and mild cognitive disorder in the
International Statistical Classification of Diseases, 10th
Revision (ICD-10)
18 refer to the cognitive consequences of
somatic disorders. Limited dementia
12 and minimal
dementia
14 clearly refer to a dementia state.AAMI
15 and
age-consistent memory impairment (ACMI)
16 address nor-
mal cognitive aging.Zaudig’s mild cognitive impairment,
17
mild cognitive decline,
13 and questionable dementia
11 rely
on global scores on cognitive-behavioral rating scales.The
major drawback of this approach is that the same score
can reflect different clinical profiles,making clinicopatho-
logical correlation and between-study comparison diffi-
cult. Late life forgetfulness (LLF)
16 assesses cognitive
deficits relative to what is considered as normal for age,
and aging-associated cognitive decline (AACD)
19 com-
pares in addition with an education- and gender-matched
relatively healthy sample.Both provide explicit inclusion
and exclusion criteria and—in the case of LLF—examples
of tests. LLF focuses on memory impairment, whereas
AACD considers additional cognitive domains (attention
and concentration,problem-solving and abstraction,lan-
guage,and visuospatial function) and enforces a 6-month
duration of decline.The Mayo Clinic criteria for mild cog-
nitive impairment (MCI)
21 are less precise and their for-
mulation has changed with time (Table II,page 66).
21,25-33As
a consequence,the heading “MCI”covers highly variable
diagnostic methodologies,hampering comparisons of stud-
ies from different research teams.
These different concepts and criteria have seldom been
compared in the same population.In a recent study,
34 111
subjects with informant evidence of cognitive decline were
classified as AAMI (n=37, 33.3%) after clinical assess-
ment.When AACD criteria were also applied,they were
fulfilled by 39 subjects (35.1%),including 20 (54%) of the
AAMIs.Moreover,as illustrated in Figure 1 (see page 66),
the cognitive profiles of subjects with AACD or AAMI
were different,with 35.9% of AACDs vs 27% of AAMIs
impaired in the memory and learning domain according
to AACD criteria (ie,at least 1 SD below age-appropriate
norms),and 35.9% AACDs vs 18.9% AAMIs impaired in
more than one cognitive domain.
34
As expected according to their individual definitions and
goals, the AAMI and AACD concepts only modestly
overlap one another; the latter captures a more severe
impairment.
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Selected abbreviations and acronyms
AACD aging-associated cognitive decline
AAMI age-associated memory impairment
ACMI age-consistent memory impairment
AD Alzheimer’s disease
CDR Clinical Dementia Rating
CERAD Consortium to Establish a Registry for
Alzheimer’s Disease
CIND cognitive impairment–no dementia 
DLB dementia with Lewy bodies
ERC entorhinal cortex
IMI isolated memory impairment
LLF late-life forgetfulness
MCI mild cognitive impairment
MMSE Mini-Mental State Examination 
MTI magnetization transfer imaging
NC normal control
NFT neurofibrillary tangle
NT neuropil thread
VaD vascular dementia
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Table I. Age-related mild cognitive deficit: definitions and criteria.
10-23 AACD, aging-associated cognitive decline; AAMI, age-associated memory impair-
ment; ACMI, age-consistent memory impairment; BVRT, Benton Visual Retention Test; CAMDEX, Cambridge Examination for Mental Disorders
in the Elderly; CDR, Clinical Dementia Rating; DSM-III-R, Diagnostic and Statistical Manual of Mental Health Disorders. 3rd ed, revised; GDS,
Global Deterioration Scale; HIS, Hachinski Ischemia score; HRSD, Hamilton Rating Scale for Depression; ICD-10, International Statistical
Classification of Diseases and Health-related Problems. 10th revision; LLF, Late-life forgetfulness; MCI, mild cognitive impairment; MMSE, Mini-
Mental State Examination; WAIS, Wechsler Adult Intelligence Scale; WMS, Wechsler Memory Scale.
Table continued on pages 64 and 65
• Benign senescent forgetfulness (1962)
10
Poor retrieval of details of a recent experience, without loss of the memory of the experience itself, with awareness of and
ability to compensate for memory troubles. The picture remained stable over time and was not associated with increased
mortality rate.
• Questionable dementia, CDR=0.5 (1982)
11
Consistent slight forgetfulness, partial recollection of events, but fully orientated except for slight difficulty with time rela-
tionships, slight impairment in solving problems, slightly impaired functioning in job, shopping, and social groups, life at
home, hobbies, and interests slightly impaired.
• Limited dementia (1982)
12
1. Subjective report of memory decline.
2. Increased reliance on notes and reminders.
3. Occasionally forgets names of acquaintances, forgets appointments, or misplaces objects.
4. Occasionally has destructive or dangerous memory lapses, such as burning cooking or leaving on gas taps.
5. Has one or two errors on cognitive testing: forgets current or past President, exact date, telephone number, postcode,
dates of marriage or moving to present location, or cannot remember interviewer’s name, even on third challenge. 
• Mild cognitive decline (1982)
13
GDS score of 3, cognitive tests performances ≥1 SD below mean for age-group, and memory complaints.
• Minimal dementia (1986)
14
A CAMDEX category, refers to individuals with a mild impairment of recall, minor and variable errors in orientation, a blunted
capacity to follow arguments and solve problems, and occasional errors in everyday tasks.
• AAMI (1986)
15
Inclusion criteria
1. ≥50 years of age.
2. Complaints of memory loss reflected in everyday problems. Onset of memory loss described as gradual, no sudden worsening.
3. Memory test performance that is ≥1 SD below the mean established for young adults on a standardized and adequately
normed test of secondary (recent) memory. Example of tests and cutoffs provided: BVRT form A ≤6; WMS logical memory
subtest ≤6; associate learning subtest ≤13.
4. Evidence of adequate intellectual function reflected in a standard score of ≥9 on the WAIS.
5. Absence of dementia reflected in an MMSE score ≥24.
Exclusion criteria
1. Delirium, confusion, or other disturbance of consciousness.
2. Any neurological disorder (determined by history, clinical neurological examination or neuroradiological examination)
that could produce cognitive deterioration.
3. History of infective or inflammatory brain disease.
4. Evidence of significant cerebral vascular pathology as determined by an HIS ≥4.
5. History of repeated minor head injury or single head injury with >1 h loss of consciousness.
6. Current psychiatric diagnosis of depression, mania, or major psychiatric diagnosis.
7. Current diagnosis or history of alcohol or drug dependence.
8.   Evidence of depression as determined by an HRSD score ≥13.
9.   Any medical disorder, determined by history, clinical examination and laboratory tests that could produce cognitive deterioration.
10. Psychotropic drug use during the month before psychometric testing.In the Canadian Study of Health and Aging,specific cri-
teria were applied in subjects classified as CIND.
22 Sixty-
five percent did not meet any of them; none met the
AAMI criteria of Bradford and LaRue.
16When inclusion
criteria were applied alone, 8.1% fitted the criteria for
AAMI, 5.9% for ACMI, 7.4% for LLF, and 34%
AACD; after applying exclusion criteria, these figures
dropped to 1.2% (AAMI), 0.9% (ACMI), 0% (LLF),
and 13% (AACD).These data highlight the importance
of exclusion criteria resulting from comprehensive clin-
ical evaluation. Only 24% of those meeting one set of
criteria also met one other or more (19.2% met two,
3.8% three,and 0.8% four),suggesting that the different
sets of criteria are mutually exclusive.In a sample of 60-
to 64-year-old healthy people,
35 13.5% met criteria for
AAMI, 6.5% for ACMI, 1.5% for LLF, and 23.5% for
AACD.Among subjects with AAMI, 22% met the cri-
teria for ACMI, 11% for LLF, and 63% for AACD.All
the LLF subjects also fulfilled criteria for both AAMI
and AACD.
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Table I. Continued.
• AAMI (1989)
16
Inclusion criteria
1. Adults 50–79 years of age.
2. Perceived decrease in day-to-day memory corroborated by standardized self-report memory questionnaires.
3. Memory test performance, in a battery of at least four memory tests, which meets one of the following: (i) AAMI: perfor-
mance ≥1 SD below the mean established for young adults on one or more test; (ii) ACMI: performance on ≥75% of the
tests that is within 1 SD of the mean established for subject’s age; (iii) LLF: performance on ≥50% of the tests that falls
between 1 and 2 SD below the mean for age. Examples of tests provided: BVRT; WMS, visual reproduction with 30-min
delay; Rey Osterreith complex figure with 3-min delay; WMS, logical memory with 30-min delay; WMS, associated learning
with 30-min delay; Rey Auditory Verbal Learning Test with 30-min delay.
4. Verbal and performance IQ score between 90 and 130 on WAIS or WAIS-Revised.
Exclusion criteria
1. Presence of any neurological or vascular disorder, determined by history, neuropsychological assessment and laboratory
tests, that could affect cognitive processing, including dementia, delirium or attentional problems indicated by a forward
digit span ≤5 and history of infective or inflammatory brain disease.
2. Current medical problems that reduce the ability to participate or directly decrease memory performance.
3. Current psychological or psychosocial stress that would interfere with assessment and treatment, including depression
reflected by a score of ≥13 on the HDRS or on the Geriatric Depression Scale, current or past drug or alcohol dependence,
and any DSM-III-R disorder that would interfere with assessment or treatment, including adjustment disorder. 
• MCI (1992)
17
Based on a performance in the test battery of the “Structured interview for the diagnosis of dementia of the Alzheimer’s type,
multi-infarct dementia and dementias of other etiology according to ICD-10 and DSM-III-R” SIDAM (score 34-49), exclusion of
dementia, no other specific etiological concept.
• Mild cognitive disorder (1993)
18
A. Meets the general criteria for “Other mental disorders due to cerebral lesion or impairment or to a somatic disorder.”
B. Presence, most of the time during at least 2 weeks, of cognitive functions disturbance, according to the subject or a reliable
informant. The disorder is characterized by impairment in at least one of the following domains:
1. Memory (particularly recent) or learning of new information.
2. Attention or concentration.
3. Thinking (eg, slowing of abstract thinking or of ability to solve problems).
4. Language (eg, comprehension, word finding).
5. Visuospatial functioning.
C. Presence of abnormalities or decline on neuropsychological testing (or other quantified cognitive evaluation). 
D. None of the disturbances B1-5 is severe enough to meet the diagnosis of dementia, amnestic syndrome, delirium, 
postencephalitic syndrome, postconcussional syndrome or another persistent cognitive failure due to the use of 
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• AACD (1994)
19
Inclusion criteria
1. Report by the individual or a reliable informant that cognitive function has declined.
2. Onset of decline must be described as gradual and have been present for ≥6 months.
3. The disorder is characterized by difficulties in any one of the following areas: memory and learning; attention and concen-
tration; thinking (eg, problem solving, abstraction); language (eg, comprehension, word finding); visuospatial functioning.
4. There is an abnormality of performance on quantitative assessments (eg, neuropsychological tests or mental status evalua-
tions) for which age and education norms are available for relatively healthy individuals. Performance must be ≥1 SD below
the mean value for the appropriate population.
Exclusion criteria
1. None of the abnormalities listed above is of sufficient degree for a diagnosis of mild cognitive disorder or dementia to be
made (there must be no objective evidence from physical and neurological examination or laboratory tests and no history
of cerebral disease, damage or dysfunction or of systemic physical disorder known to cause cerebral dysfunction).
2. Depression, anxiety or other significant psychiatric disorders that may contribute to observed difficulties.
3. Organic amnestic syndrome.
4. Delirium.
5. Postencephalitic syndrome.
6. Persisting cognitive impairment due to psychoactive substance use or the effect of any centrally acting drug.
• Mild neurocognitive disorder (1994)
20
A. The presence of 2 or more of the following impairments in cognitive functioning lasting most of the time for a period of
≥2 weeks (as reported by the individual or a reliable informant):
1. Memory impairment as identified by a reduced ability to learn or recall information.
2. Disturbance in executive functioning (ie, planning, organizing, sequencing, abstracting).
3. Disturbance in attention or speed of information processing.
4. Impairment in perceptual-motor abilities.
5. Impairment in language (comprehension, word finding).
B. There is objective evidence from physical examination or laboratory findings (including neuroimaging techniques) of a neu-
rological or general medical condition that is judged to be etiologically related to the cognitive disturbance. 
C. There is evidence from neuropsychological testing or quantified cognitive assessment of an abnormality or decline in per-
formance. 
D. The cognitive deficits cause marked distress or impairment in social, occupational, or other important areas of functioning
and represent a decline from a previous level of functioning. 
E. The cognitive disturbance does not meet criteria for a delirium, a dementia, or an amnestic disorder and is not better
accounted for by another mental disorder (eg, a substance-related disorder, major depressive disorder). 
• MCI (1995)
21
1. Memory complaint by patient, family, or physician.
2. Normal activities of daily living.
3. Normal global cognitive function.
4. Objective memory impairment or impairment in one other area of cognitive function as evidenced by scores >1.5 SD below
age-appropriate mean. 
5. CDR=0.5. 
6. Not demented.
• Cognitively impaired, not demented (1995)
22
1. Modified MMSE
23 (3MS) score ≤77.
2. No dementia, based on: history; informant interview; physical examination; detailed neurological examination; neuropsy-
chological tests (if 3MS>50) comprising: memory, abstract thinking, judgment, constructional abilities, language, familiar
object recognition, digit symbol substitution test. 
Table I. Continued.Together these results are not very surprising.First,the dif-
ferent sets of criteria refer to different concepts (AAMI
and ACMI versus LLF and AACD,see above).Second,
they basically consist of a priori constructs, differing in
their criteria and cutoff scores,and not of the description
of clinical populations.Third,because of criteria’s method-
ological vagueness (eg,no firm reference tests;no indica-
tion on whether one function should be assessed using one
or several tests),they offer room for different implemen-
tation across teams.The impact of introducing changes in
criteria is illustrated by the Eugeria Project.
36 Of 833 sub-
jects recruited,308 fulfilled the first two criteria for MCI
(subjective memory complaint and normal general intel-
lectual functioning, as assessed by performance on a
vocabulary test);of these,103 had a decrement of more
than 1 SD on a memory task,relative to normal values for
age and educational level (criterion 3);exclusion of sub-
jects with difficulties in any other cognitive domain left
only 27 subjects fulfilling the criteria;application of crite-
rion 4 (normal activities of daily living) had no influence.
Thus,modification of the third criterion reduced the preva-
lence of MCI from 12.4% to 3.2%.The AACD criteria
applied to the same population identified 174 participants
(20.8%),which included all the MCI subjects.
Neuropathological correlates
To the best of our knowledge,the only concept that has
been compared with neuropathological examination is
MCI as defined by the Mayo Clinic team.
21 In a follow-
up study,
37 6 out of 6 subjects with a Clinical Dementia
Rating (CDR)
32 score 0.5 resulting from memory impair-
ment alone were found to meet modified
38 Kachaturian
39
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Table II. Definition and criteria for mild cognitive impairment (MCI).
21,25,26 ADL, activities of daily living; CDR, Clinical Dementia Rating; DSM-III-R, Diagnostic
and Statistical Manual of Mental Health Disorders. 3rd ed, revised; MMSE, Mini-Mental State Examination. *Although CDR score
32,33 was not
a criterion, MCI subjects had CDR=0.5.
1995
21 • Cognitive complaints (usually memory)
• Cognitive screening tests in normal range for age (MMSE
27/Short Test of Mental Status
28)
• Performances on memory tests >1.5 SD below age-appropriate norms
• Preserved ADL (history, Blessed Dementia Scale,
29 Record of Independent Living
30
• No dementia (DSM-III-R
31 criteria)
• CDR=0.5
32
1999
25* • Memory complaint
• Normal ADL
• Normal general cognitive function
• Abnormal memory for age
• No dementia
2001
26 • Memory complaint, preferably corroborated by an informant
• Objective memory impairment
• Normal general cognitive function
• Intact ADL
• Not demented
Figure 1. Cognitive profile in age-associated memory impairment (AAMI)
and aging-associated cognitive decline (AACD) subjects, accord-
ing to the data in reference 34. Memory: according to AACD
criteria (at least 1 SD below age-appropriate norms). IMI, iso-
lated memory impairment; >1 function, impairment in more
than one function.
0
10
15
20
25
S
u
b
j
e
c
t
s
 
i
m
p
a
i
r
e
d
 
(
%
)
5
30
35
40
45
Attention/calculation
Language
Memory
IMI
Thinking
>1 function
Visuospatial
Comparative cognitive profile in AACD and AAMI
AACD
AAMIneuropathological criteria for AD.This confirmed previ-
ous data
40 showing that 10 out of 10 subjects with
CDR=0.5 had histopathological AD, versus none of 4
with a score of 0. In another study,
41 subjects with a
CDR≥0.5 had large senile plaque densities in the neo-
cortex and the degree of dementia seemed related to an
increase in the ratio of neuritic to diffuse plaques.While
cognitively healthy controls—and even individuals with
preclinical AD—had no significant decrease in neuronal
count in the entorhinal cortex (ERC) as a whole,in ERC
layer II or in the CA1 hippocampal field,the brains of
subjects with CDR=0.5 were characterized by a signifi-
cant neuronal loss in these areas.
42These studies suggest
that “questionable dementia”or isolated memory impair-
ment sufficient to yield CDR=0.5 actually represent very
mild AD.It can be questioned whether CDR=0.5 equates
to MCI.A series of studies
43-45 compared MCI subjects
(defined as being impaired in one domain on neuropsy-
chological testing,but not being found to have dementia
by the examining neurologist according to NINCDS/
ADRDA [National Institute of Neurological and
Communicative Diseases and Stroke/ Alzheimer’s
Disease and Related Disorders Association] criteria
46)
with normal controls (NCs) and AD patients,all from a
group of catholic clergy participating in the Religious
Order Study (Table III).Both AD patients and MCI sub-
jects had a lower ERC layer II neuronal count,remain-
ing neuronal volume,and global volume.However,MCIs
and AD patients significantly differed in layer II global
volume only, despite a group effect in analysis of vari-
ance,while all the AD and NC values were significantly
different.Global and neuronal atrophy were correlated
with impairment of delayed and immediate recall.
44
Quantified ERC β-amyloid (βA) load
43 in MCIs was
intermediate, but not significantly different from that
found in NCs and AD patients respectively (again,NC vs
AD values were significantly different),although analy-
sis of variance revealed a significant group effect with a
trend to linear increase from NCs to MCIs to AD
patients.It is noteworthy that some NC or MCI subjects
had βA load equal to or higher than that seen in many
AD patients,and two MCIs had no detectable βA.The
inverse correlation between Mini-Mental State Examin-
ation (MMSE)
27 scores (mean scores: 27.3 in NCs and
MCI patients,and 24 in AD patients) and βA load was
not significant.In this study,6 of 12 MCI subjects had a
neuropathological diagnosis of possible AD according to
the criteria of the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD).
47 In a third study,
45 neu-
rofibrillary tangles (NFTs) and neuropil threads (NTs)
were present in perirhinal cortex and ERC in NCs,MCI
subjects,and AD patients;the average number of NFTs
increased with the diagnosis from NC to MCI to AD.
Between-group differences analysis again found that
MCI subjects were intermediate,but not significantly dif-
ferent from either NCs or AD patients.NFT density was
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Table III. Neuropathological characteristics of mild cognitive impairment in the Religious Order Study.
43-45 CERAD, Consortium to Establish a Registry for
Alzheimer’s disease; MCI, mild cognitive impairment; NS, not significant; S, significant. Changes in MCI and AD group are given relative to
normal controls.
Normal controls MCI subjects AD patients
Layer II neuronal count S -63.55% NS -58.13%
><
Layer II neuronal volume S -24.1% NS -25.1%
>>
Layer II global volume S -26.5% S -43.4%
>>
β-Amyloid load NS +96% NS +245%
<<
Neurofibrillary tangle density NS NS
<<
Neuropathological diagnosis (CERAD)
No Alzheimer’s disease 11/20 6/12 0
Possible Alzheimer’s disease 9/20 6/12 1/12
Probable Alzheimer’s disease 0 0 4/12
Definite Alzheimer’s disease 0 0 7/12inversely correlated with episodic memory score,but not
with other, nonmemory, cognitive abilities across the
three groups.
These studies first show that no more than 50% of MCIs
were incipient AD. This is less than in the studies by
Morris
37,40 and Price,
41 and suggests that the populations
described were not equivalent,although the use of dif-
ferent neuropathological diagnostic criteria makes the
comparison difficult.Approximately the same proportion
of NCs (45%) were also diagnosed as possible AD;this
finding suggests that the clinical diagnostic tools were
neither sensitive nor specific in the detection of incipient
AD.This can be explained by the fact that both the NC
and MCI groups had high and similar MMSE scores,but
the concept of MCI precisely intends to detect cases
missed by more global testing.Nevertheless,MCI sub-
jects globally were,for most ERC lesions,intermediate
between NC and AD cases. This suggests that ERC
lesions could be a better neuropathological marker of
MCI than the presence of those required for a diagnosis
of AD.However,the fact that group-to-group compar-
isons failed to distinguish MCIs from ADs makes cur-
rently impossible to determine practically useful cutoff
values.If this failure is due to sample size,larger studies
should solve it.However,it could also be due to hetero-
geneity;clinicopathological studies seeking pathological
markers of both non-AD dementias and AD should con-
firm or rule out this possibility.Awaiting further studies,
the lack of significant difference between MCI and AD,
which was also found for high (trkA)
48 and low (p75
NTR)
49
expression of nerve growth factor receptors,suggests that
the transition from MCI to AD is not merely quantita-
tive.
Predictive value
Another way of understanding these concepts and cri-
teria is through their ability to predict the progression of
patients. Follow-up studies
21,25,36,37,50-59 differ in their dura-
tions, making comparisons difficult; dividing the fre-
quency of progression toward dementia by duration of
follow-up gives an estimate of the annual rates of “con-
version”(Table IV).
Thus,a significant proportion of subjects did not become
demented. It could be argued that a longer follow-up
would increase the “conversion” rate. However, data
from some studies reporting multiple evaluations
21,58,60-62
suggest that the incidence of dementia could decrease
over time.In a recent study with assessments at 3 and 6
years in subjects with CIND,aged 80 years or older,
61 it
was found that,according to the severity of impairment
at baseline,84% to 89% of those who were demented at
6 years had already received the diagnosis at 3 years.In
another study in oldest old (84 to 90 years old at base-
line) over 6 years,
60 a decrease in the progression from
MCI to dementia with time was also reported.This atten-
uation of the rate of progression with time could be an
artifact, since in these two studies—and also in one in
slightly younger subjects
57—MCI increased the risk of
death by 1.7
58 to 7
60 during a 4-year period.In this case,
there should be a correlation between the severity of cog-
nitive impairment at baseline and the risk of death.Such
a trend was found in one study,
58 but not in another,
61 and
in a third
60 baseline performances in the deceased group
were lower than those of survivors,but higher than for
those who progressed to dementia.Thus,the issue of the
slope of the rate of progression deserves further atten-
tion,particularly in relation to age at onset of cognitive
impairment.
Because the main criteria were set to capture degenera-
tive cognitive impairment (ie,without identifiable med-
ical cause),an intriguing finding is that a substantial pro-
portion of subjects were found to improve over time
(4.8% after 3 years in subjects with CDR=0.5
63; 19.5%
after 2.7 years in MCI as defined by Zaudig
54;25% after
3 years and 12% to 17% after 6 years in CIND
61).In clin-
ical practice, such an outcome would be ascribed to a
diagnostic error (ie,impairment was due to a unidenti-
fied medical condition).An alternative explanation is
that the underlying process is different from AD.Indeed,
a fluctuating course is classically described in vascular
dementia (VaD)
64 and dementia with Lewy bodies
(DLB).
65 In line with this hypothesis is the finding that,
in a sample of MCI subjects, 20.5% developed VaD
within 3.9 years;nothing in their baseline cognitive pro-
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Table IV. Annual conversion rates according to classification criteria.
Annual conversion rates were obtained by dividing the reported
incidence by the length of follow-up in each study.
Criteria Conversion rate (%)
Age-associated memory impairment 0–2.5
Clinical Dementia Rating scale 0.5,  4–16.6
no dementia
Mild cognitive impairment (Zaudig) 6.5
Age-associated cognitive decline 9.5–16.6
Mild cognitive impairment (Mayo Clinic) 12–16file or their progression (based on MMSE) differentiated
them from those who progressed to AD (47.9%).
62,66A
third explanation is that the criteria do not describe a sta-
ble state. The Eugeria Project compared MCI (with
impairment in memory,but not in any other domain) and
AACD over 3 years,
36 and showed that 7.5% of MCI sub-
jects retained the diagnosis from the first to second
assessment and 17.4% from the second to third;the cor-
responding figures for AACD subjects were 56.3% and
59.4%.Apart from those who became demented, sub-
jects met criteria for the alternative diagnosis (from MCI
to AACD and vice versa) or were found to be normal.In
this study,the AACD diagnosis had a sensitivity of 94.7%
and a specificity of 54.1%, whereas the MCI diagnosis
had a sensitivity of 5.3% and specificity of 91.3% in the
prediction of progression toward dementia after 2 years.
In another community-based French study,
59 the MCI
diagnosis was also found to be unstable.
According to the cited studies, there is no doubt that
mild cognitive deficit in elderly subjects, whatever its
definition and criteria, increases the risk of developing
dementia. The available data provide a rather broad
range of annual incidence of dementia and are not all in
favor of a linear prevalence–time relationship in mildly
impaired patients.The proposed sets of criteria have dif-
ferent stability and predictive values.Also, they do not
allow identification of individuals who will develop
dementia or—more importantly—the type of dementia
toward which they could evolve.
Beyond the criteria themselves, several studies found
predictors of progression to dementia or even to AD in
measures derived from the MMSE,
62 the CDR,
63 or
impairment in memory,verbal fluency,and attention on
more conventional neuropsychological tests.
52,67-69 As
pointed out by Tuokko and Frerichs,
70 a major short-
coming of these data is that they are retrospective. No
combination of cognitive tests has yet been assessed
prospectively for its ability to predict outcome in mildly
impaired patients. If it were done using neuropsycho-
logical batteries that were sufficiently refined for early
identification of the characteristic signs of the major
dementing diseases and determination of reliable cutoff
scores,then this type of investigation would be reserved
for specialized teams;however,the first person who peo-
ple with cognitive complaints see is their general practi-
tioner. It is expected that this dilemma will be partly
solved in the near future by recourse to investigational
techniques.
Contribution of investigational techniques
For decades,the scientific community has been seeking
biomarkers of AD, using genetics, neurochemistry, and
imaging techniques. It was rational to apply these tech-
niques to mild cognitive deficit,in order to characterize
these states and identify predictors of progression to AD.
Neuropathological studies have shown the hippocampus
to be one of the earliest affected structures in AD,
71 and so
it is a region of choice for neuroimaging studies.Although
hippocampal atrophy, as measured by volumetric tech-
niques is not entirely specific,it is now considered to be a
hallmark of AD,
72 and its absence in addition to minor or
unilateral atrophy is believed to be strong evidence against
the diagnosis.In mild cognitive deficit,several studies have
shown lesser
73-76 or similar
77 hippocampal atrophy to that
found in AD. Age transformation of combined hip-
pocampal and amygdala volume increases the accuracy of
classifying AD,MCI,and normal elderly subjects.
78 MCI
subjects had hippocampal volume correlated with cogni-
tive and performance measures
79 and those who declined
over time had also a greater annualized rate of hip-
pocampal atrophy than nondecliners,close to that of AD
patients.
80Atrophy of various regions at baseline,includ-
ing hippocampus
79,81,82 ERC,
83,84 fusiform gyrus,
85 caudal cin-
gulate cortex,
83 and medial temporal lobe,
76 was found pre-
dictive of progression to AD.White matter lesions have
been found to be associated with subjective cognitive
decline,
86 lowered attention and speed of mental process-
ing,
87 and progression to dementia.
88
There is an agreement on the fact that established AD is
characterized by altered cerebral blood flow (CBF) and
metabolism in posterior parietal and temporal lobes as
well as by,according to stage and neuropsychological pro-
file,frontal cortex deficits,and hemispheric asymmetry.
89
That functional imaging is able to detect preclinical AD
is suggested by positron emission tomography (PET)
studies,which found regional cerebral glucose metabo-
lism (rCMRGlu) alterations in nondemented subjects at
risk of AD (ie,those carrying the apolipoprotein E type 4
allele [ApoE ε4] and with familial history of AD)
90,91;those
in the inferior parietal and posterior cingulate cortices
correlated with later memory decline.
92
Studies comparing CBF and rCMRGlu in normal and
mildly impaired subjects found deficits in the latter, in
various regions including bilateral parietal cortex,
56 hip-
pocampus,
77 and posterior cingulate gyrus.
93-95 Prediction
of outcome was found for defects in parietal or tem-
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69poroparietal cortex,
56,96 posterior cingulate gyrus,
94,95 and
for temporoparietal asymmetry
97 and lowered pos-
teroanterior ratio
89; others were predictive when com-
bined with performance on specific cognitive tasks
98,99
and/or demographic characteristics.
99
Progress in functional imaging can come from activation
studies. Comparisons of young to elderly healthy sub-
jects have shown that poorer performances in tasks such
as conflict resolution and episodic memory in the elderly
corresponded to underactivation, whereas a perfor-
mance similar to that of young controls in working mem-
ory tasks was accompanied with recruitment of addi-
tional brain regions.
100 Studies comparing activation
during cognitive tasks in AD patients and controls
101-105
showed that, together with lower performances, AD
patients had activation patterns characterized by
absence of activation in some brain areas,activation with
shifted peak foci,expansion of normally activated zones,
and recruitment of remote areas.
103 These differences
were generally interpreted as due to compensation
efforts; complementary interpretations are disconnec-
tion between regions normally involved in the task and
predominant processing of accessory aspects of the stim-
uli (eg, emotional appearance in face recognition).
105
Passive pattern-flash stimulation elicited less activation
in AD patients; this failure requires a less demanding
stimulation to be disclosed in the moderate-to-severe
group than in the mild group.
106
Cognitively normal subjects at risk for AD (defined as
the presence of at least one ApoE ε4 allele, alone
107 or
combined with a history of AD in at least one first-
degree relative
108) were compared with low-risk controls
for activation induced by cognitive tasks they performed
with the same accuracy level. In the high-risk group,
some regions were activated to a greater extent or mag-
nitude (eg, nearly twice as much as in controls in hip-
pocampal regions
107);others displayed lower activation.
108
After a 2-year follow-up,
107 decline in verbal recall cor-
related with the number of regions activated in the left
hemisphere at baseline.
Using a functional magnetic resonance imaging (fMRI)
protocol specifically developed for hippocampal region
analysis,one study
109 compared cognitively NCs,subjects
with isolated memory impairment (IMI), and AD
patients during a simple task (gender discrimination of
presented faces); all subjects performed the task with
100% accuracy.AD patients had lesser activation of the
three regions studied, ie, ERC, subiculum, and the hip-
pocampus proper.Among the IMI subjects, one third
had an activation pattern similar to that of AD patients
and the others displayed lesser activation in the subicu-
lum only. Follow-up data would be necessary to deter-
mine whether the differences described in this study are
predictive,but together these activation studies indicate
that properly chosen activation paradigms could help
identify AD in subjects with mild cognitive deficits.
Nuclear magnetic resonance affords additional
approaches. Magnetic resonance spectroscopy (MRS)
can assess the biochemical composition of living brain
regions.To date, the most consistent findings in AD
110
have been obtained with proton MRS showing a
decrease in N-acetylaspartate (NAA) and an increase in
myoinositol (MI). NAA and MI changes are specific to
neither AD nor brain disease,but the NAA/MI ratio can
discriminate possible AD cases from NCs. In addition,
NAA/MI, NAA, and the MI/creatine (Cr) ratio were
shown to be correlated with MMSE score in controls
and patients with probable AD
111;in a 12-month follow-
up study
112 NAA/Cr and NAA/MI at baseline were cor-
related with the progression of MMSE scores.Few stud-
ies have used MRS in mild cognitive deficit. MI/Cr was
found to be higher in MCI subjects
113,114 and NAA lower
in AAMI subjects
115 and AD patients than in controls,
whereas MI values were intermediate between AD
patients and controls.
115 Follow-up studies are necessary
to confirm the predictive value of such findings.
The magnetization transfer imaging (MTI)
116 signal
arises from the magnetization exchange between water-
and macromolecule-bound protons; this technique is
useful in the study of membranes and membrane-linked
diseases such as multiple sclerosis, in which decreased
magnetic transfer ratio (MTR) is a marker of demyeli-
nation
117 and axonal density loss.
118 MTI studies involv-
ing AD patients
119-125 agree on decreased values com-
pared with NCs, expressing structural changes in the
temporal lobe, and also the frontal lobe and the whole
brain.
119,120 Hippocampal MTR had a discrimination rate
relative to controls of 85% in mild AD (CDR=0.5),89%
in mild AD (CDR=1), and 100% in moderate AD
(CDR=2); the values for visually rated atrophy were of
73%, 80%, and 91% respectively.
124 MTR was also able
to differentiate AD from non-AD dementia with a suc-
cess rate of 77%.
123 Studies comparing MCI subjects with
AD patients and healthy controls
119-122 identified struc-
tural changes in MCI in the absence of significant atro-
phy; they were located in gray matter, whereas those
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122
These changes were found to be correlated with cogni-
tive impairment.
119,120 MTI thus seems able to identify
structural changes before atrophy is manifest.Follow-up
studies should confirm its predictive value and compar-
ison with functional imaging should assess which tech-
nique detects the earlier changes.
The ApoE ε4 allele is acknowledged to be a risk factor for
AD.
126,127 Few studies have specifically addressed its influ-
ence on the evolution of MCI subjects.The ApoE ε4 car-
rier status was found the best predictor of conversion to
AD (risk ratio=4.36),
21 a nonsignificant predictor (relative
risk of 1.49)
79 or to have no predictive value.
54,128 In subjects
with memory impairment and Global Deterioration Scale
(GDS) score of 2 to 3,
129ApoE ε4 alone predicted progres-
sion to dementia with a 73.8% accuracy;combining geno-
type and memory scores increased the accuracy to 92.5%.
In subjects with MMSE scores of 21 to 26,the ApoE geno-
type was found to be associated with an odds ratio for pro-
gression to dementia of 3.31
130 and with memory decline.
131
Among the various substances that have been assayed
in blood and CSF,
132 increased CSF-tau and decreased
βA1-42 proteins are the best markers for AD to date.
132-134
Their combination yielded a 94% and 88% sensitivity
for probable and possible AD, respectively, and speci-
ficity of 100% versus psychiatric disorder, 89% versus
no dementia,67% versus DLB,and 48% versus VaD in
clinical practice conditions.
135 CSF-tau levels were found
to be higher in MCI than in healthy controls,
136-140 lower
than
141 or similar to
139,140 those found in AD patients. In
follow-up studies,it identified MCI subjects who evolved
to AD with a sensitivity of 65% to 68% and a specificity
of 100% versus patients with memory complaints
142 and
93% versus healthy controls
139; baseline values in con-
verters were higher than in nonconverters.
137 In one
study,
139 combining CSF-tau and βA1-42 values did not
improve the predictability obtained with CSF-tau alone.
In others,combined CSF-tau/βA1-42 values differentiated
converters from healthy controls with 88% sensitivity
and 80% specificity
138 and from nonconverters with a
90% sensitivity and specificity.
140
Medical diagnoses are rarely reached using a single
marker;most often it results from the combination of dif-
ferent approaches,including thorough clinical evaluation.
Once a consensus is obtained on cutoff values for the dif-
ferent techniques mentioned,it is likely that a combina-
tion of different markers for AD will allow early diagno-
sis with high sensitivity and specificity in individual cases.
Therapeutic aspects
The final goal of constructing criteria for age-associated
mild cognitive deficit is to treat it, and many therapeu-
tic approaches are available.
143,144
Some benefits have been reported,in terms of global sta-
bility and improved memory with the acetylcholinesterase
inhibitors (AChEI) donepezil
145 and rivastigmine
146 and the
dopamine receptor agonist/α2 antagonist piribedil
147;trials
are underway using donepezil and vitamin E,rivastigmine,
the cyclooxygenase-2 (COX-2) inhibitors celecoxib and
rofecoxib with the goal of delaying patients’ progression
to dementia
144 and the Ampakine
® CX516 with the aim of
short-term symptomatic improvement.
148 Treating MCI
using approaches initially intended for AD premises either
that MCI equates to early AD in all cases, which is
unlikely,or that the underlying mechanism is the same in
both cases,the difference being merely a matter of inten-
sity, which is not confirmed by neuropathological data.
Even if improved criteria or techniques were able to pre-
dict the progression to AD in a given patient,this strategy
deserves discussion.As regards the cholinergic and glu-
tamatergic systems in AD,it has been proposed that the
final deficiency state is preceded,in the early stages,by a
hyperactive state
149,150 originating in βA-induced N-methyl-
D-aspartate (NMDA) receptor hypersensitivity. It was
recently found that the number of choline acetyltrans-
ferase (ChAT)–positive neurons in the nucleus basalis of
Meynert was no lower in MCI than in NCs.
151 Further,
ChAT activity was shown to be increased in hippocampus
and in the superior frontal cortex compared with NCs,and
similar in anterior cingulate,superior temporal,and infe-
rior parietal cortices.
152Although such data are lacking for
the glutamatergic system, these findings suggest that,
among the currently available treatments,those aiming at
downmodulating the NMDA receptor responsiveness
could be more appropriate than replacement therapies in
degenerative,AD-type MCI.Mild cognitive deficit will be
the condition of choice for administration of future treat-
ments addressing basic mechanisms of degenerative
dementias,provided they can be reliably identified in these
patients.
Conclusion
Introducing criteria for mild cognitive deficit should:
• Help its detection,mostly in first-line medicine.
• Improve the accuracy of early dementia diagnosis.
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71•Through harmonization of practice in research set-
tings, permit progress in pathophysiological and ther-
apeutic research.
All the sets of criteria,whatever their formulation,require
the input of a neuropsychologist and a thorough, com-
prehensive examination.This approach is available in spe-
cialized centers only, and not transferable to first-line
medicine.The criteria by themselves do not predict which
individual will progress to dementia and still less the
nature of this potential disease.On the other hand,early,
reliable diagnosis of AD through a proper combination
of investigational procedures can be expected in the near
future.Epidemiological data show that AD remains the
most frequent dementia type in elderly people.
153 Follow-
up studies suggest that it is also the most frequent demen-
tia type developed by subjects with mild cognitive deficit.
Therefore,early identification or rejection of AD would
solve the majority of cases.It can thus be thought that the
priority is to optimize our battery of investigational tools
by defining appropriate cutoff values,comparing them in
the same patient samples,and defining their individual
powers.
From a practical and clinical point of view,refining the
sets of criteria to improve their specificity,which implies
skilled professional intervention, is probably useless.
Efforts should rather be made to define simple,sensitive
tools,usable by general practitioners.
From a research point of view, it seems mandatory to
reach a consensus on several points.Should the reference
population be matched for age only,or for gender and
education as well? Using age-related references implies
admitting that cognitive decline occurs in healthy aging;
using education-related ones implies that low education
is an independent risk factor for cognitive decline
154,155;
using gender requires taking into account the hormonal
status of women. Should impairment in a cognitive
domain be established on the basis of a single test,or of
several ones addressing the same function? Should stud-
ies include subjects with memory impairment only, or
with decline in other domains as well? Stratifying the
participants according to their cognitive profile would
allow assessment of the predictivity of this item,relative
to the underlying disease,as proposed by Petersen et al.
156
It would also permit comparison of the effect of treat-
ments in these subsets.
These issues cannot be solved by any single research team.
Collaborative or,at least,comparable studies require the
strict definition of common basic inclusion (eg,the tests to
be used with standard cutoff scores) and exclusion criteria.
Before being applicable in daily practice,the available
sets of criteria need to be further defined and standard-
ized. The current lack of treatment is a hurdle to its
acceptance.However,disseminating the concept could
help increase the sensitivity of general practitioners to
the importance of cognitive complaints and signs in their
elderly patients. ❏ 
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El déficit cognitivo leve relacionado con la
edad: ¿un concepto a punto de usarse?
Para un mejor manejo del deterioro cognitivo leve
en los pacientes ancianos, los clínicos deben contar
con instrumentos para detectar cambios precoces y
predecir su progresión. Para definir este estado cog-
nitivo entre el envejecimiento óptimo y el patológico
se han propuesto muchos conceptos, los cuales inclu-
yen diversas condiciones y proporcionan criterios más
o menos precisos, dejando libertad para una imple-
mentación variable. Como consecuencia de esto, la
aplicación de estos criterios determinó frecuencias
de prevalencia altamente variables. Los estudios neu-
ropatológicos indican que los diferentes criterios tie-
nen un poder variable para detectar la Enfermedad
de Alzheimer (EA) incipiente y sugieren que la tran-
sición entre el deterioro cognitivo leve y la EA no es
meramente cuantitativa. Los estudios de segui-
miento han determinado– de acuerdo con los crite-
rios utilizados –una frecuencia anual de progresión
hacia la demencia entre un 2,5% y un 16,6%, y tam-
bién han mostrado que los criterios difieren en su
estabilidad y poder predictor. Los resultados cogniti-
vos basales tienen algún valor predictor, pero son
difíciles de aplicar en la atención primaria. Las técni-
cas paraclínicas (las imágenes estructurales y funcio-
nales, la resonancia magnética por espectroscopía,
las imágenes por transferencia de magnetización, la
neuroquímica del líquido céfalo-raquídeo y el geno-
tipo de la apolipoproteína E) constituyen herra-
mientas promisorias en el diagnóstico precoz de la
EA, la cual se mantiene como el tipo más frecuente
de demencia en la población anciana y probable-
mente también el más frecuente que se desarrolla
en pacientes con déficit cognitivo leve. El objetivo
final es ofrecer un tratamiento precoz a aquellos
pacientes que evolucionarán hacia la demencia, una
vez que ellos se hayan podido  identificar. En el caso
de la EA los hallazgos recientes cuestionan la conve-
niencia de terapias colinérgicas de reemplazo.
Actualmente los criterios para el déficit cognitivo
leve son difíciles de aplicar a la atención primaria. Sin
embargo, la divulgación del concepto podría ayudar
a aumentar la sensibilización de los médicos gene-
rales respecto a la importancia de signos y quejas
cognitivas en sus pacientes ancianos.
Troubles cognitifs légers liés à l’âge : 
un concept prêt à l’emploi ?
La prise en charge efficace des troubles cognitifs
légers chez les patients âgés implique que les méde-
cins puissent disposer d’instruments capables de
détecter des modifications précoces et de prévoir leur
évolution. Divers concepts, décrivant en fait des situa-
tions variées et utilisant des critères plus ou moins
précis, ont été proposés pour définir cet état cogni-
tif intermédiaire entre vieillissement optimal et pat-
hologique. Par conséquent, l’application de ces critè-
res a fourni des taux de prévalence eux-mêmes très
variables. Les études neuropathologiques montrent
que les différents critères ont un pouvoir variable
pour détecter une maladie d’Alzheimer débutante
(MA) et suggèrent que la transition entre trouble
cognitif léger et MA avérée n’est pas seulement d’or-
dre quantitatif. Les études de suivi ont montré que
les critères utilisés diffèrent quant à leur pouvoir pré-
dictif et leur stabilité, aboutissant à des chiffres
annuels de progression vers la démence variant entre
2,5 % et 16,6 %. Les performances cognitives basales
ont une certaine valeur prédictive mais sont difficiles
à appliquer en médecine de premier recours. Les exa-
mens paracliniques (imagerie fonctionnelle et struc-
turelle, spectroscopie par résonance magnétique,
imagerie par transfert de magnétisation, neurochi-
mie du liquide céphalorachidien et génotype des
apolipoprotéines E) sont des outils prometteurs dans
le diagnostic précoce de la MA qui reste le type de
démence le plus fréquent chez les sujets âgés et pro-
bablement la pathologie qui se développe le plus
souvent chez les patients atteints de troubles cogni-
tifs légers. Le but final est d’offrir un traitement pré-
coce à ceux qui évolueront vers la démence dès qu’ils
auront pu être identifiés. Pour ce qui est de la MA,
des observations récentes remettent en cause les trai-
tements substitutifs cholinergiques. Dans leur état
actuel, les critères du déficit cognitif léger sont dif-
ficilement applicables en médecine de premier
recours. Néanmoins, la diffusion de ce concept pou-
rrait aider à sensibiliser les médecins généralistes à
l’importance des manifestations tant subjectives
qu’objectives indiquant une atteinte cognitive chez
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